CRDF
NASD Cardiff Oncology, Inc.$0.8857 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.8857, $0.0435 below the day’s high of $0.9292
- YTD change
- -68.48%
- vs 20-day SMA
- -22.12%
- vs 200-day SMA
- -42.44%
Price ranges
Price & Performance
-0.89 (-50.24%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.5% away from all-time highs of $25.5000
- CRDF is down 68% since the beginning of the year
- CRDF is down 60% over the past 12 months
- CRDF is down 35% over the past 1 month
- 16% of all CRDF investors are betting against CRDF
CRDF reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -61.2%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0030
- Last 5 days
- -17.99%
- vs 8-day SMA
- -12.80%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
